Table 1.
Characteristics of patients and controls included in the preliminary analyses of the ANRS0001 S COV-POPART cohort study
| Specific population (n = 2979) |
Control group <65 y (n = 962) |
Control group ≥65 y (n = 150) |
||||
|---|---|---|---|---|---|---|
| Characteristics | n | Median (IQR) or n (%) | n | Median (IQR) or n (%) | n | Median (IQR) or n (%) |
| Age (y) | 2974 | 52.5 (41.9–61.3) | 962 | 43.9 (34.1–52.1) | 150 | 70.8 (68.1–74.7) |
| Men | 2979 | 1504 (50.5) | 962 | 473 (49.2) | 150 | 70 (46.7) |
| Population | 2979 | — | — | |||
| Cancer | 188 (6.3) | — | — | |||
| Solid organ transplant | 198 (6.6) | — | — | |||
| Hematopoietic stem cell transplant | 122 (4.1) | — | — | |||
| Chronic renal failure with or without dialysis | 95 (3.2) | — | — | |||
| Systemic autoimmune diseases | 173 (5.8) | — | — | |||
| Inflammatory rheumatic diseases | 191 (6.4) | — | — | |||
| Multiple sclerosis or neuromyelitis optica spectrum disorders | 416 (14.0) | — | — | |||
| Hypogammaglobulinemia | 70 (2.3) | — | — | |||
| Diabetes | 445 (14.9) | — | — | |||
| Non-diabetic with obesity | 820 (27.5) | — | — | |||
| Patients with HIV | 897 (30.1) | — | — | |||
| Type of vaccine | 2919 | 955 | 149 | |||
| BNT162b2 + BNT162b2 | 2163 (74.1) | 854 (89.4) | 138 (93.3) | |||
| BNT162b2 + BNT162b2 + BNT162b2 | 426 (14.6) | — | — | |||
| mRNA-1273 + mRNA-1273 | 230 (7.9) | 92(9.6) | 10 (6.7) | |||
| mRNA-1273 + mRNA-1273 + mRNA-1273 | 78 (2.7) | — | — | |||
| BNT162b2 + mRNA-1273 | 15 (0.5) | 9 (0.9) | 0 (0.0) | |||
| BNT162b2 + BNT162b2 + mRNA-1273 | 3 (0.1) | — | — | |||
| BNT162b2 + mRNA-1273 + mRNA-1273 | 4 (0.1) | — | — | |||
| Number of doses | 2979 | 962 | 150 | |||
| 2 | 2457 (82.5) | 962 (100.0) | 150 (100.0) | |||
| 3 | 522 (17.5) | 0 (0.0) | 0 (0.0) | |||
| Hemoglobin (g/dL) | 2296 | 14.1 (13.0–15.2) | 872 | 14.0 (13.2–15.1) | 146 | 14.0 (13.4–14.8) |
| White blood cells (cells/μL) | 2294 | 6390 (5130–7800) | 871 | 6000 (5130–7100) | 145 | 6180 (5300–7130) |
| Neutrophils (cells/μL) | 2284 | 3700 (2800–4750] | 870 | 3480 (2890–4320) | 145 | 3770 (2920–4570) |
| Platelets (10/mm3) | 2292 | 249 (210–292) | 869 | 250 (215–284) | 146 | 247 (219–280) |
| Creatinine (μmol/L) | 2276 | 72.0 (62.0–87.0) | 867 | 70.0 (61.0–80.0) | 144 | 71.0 (64.0–81.5) |
| Alanine aminotransferase (IU/L) | 730 | 25.0 (18.0–37.0) | 0 | — | 0 | — |
| Aspartate aminotransferase (IU/L) | 729 | 22.0 (18.0–28.5) | 0 | — | 0 | — |
| C-reactive protein (mg/L) | 2070 | 3.0 (1.1–4.6) | 787 | 1.2 (1.0–4.0) | 100 | 3.8 (1.0–4.0) |
| C-reactive protein ≥5 mg/L | 2070 | 416 (19.6) | 787 | 37 (4.7) | 100 | 9 (9.0) |
| Lymphocytes <1000 G/L | 2284 | 225 (9.6) | 870 | 44 (5.1) | 145 | 7 (4.8) |
All characteristics were recorded at the time of inclusion into the cohort. HIV, human immunodeficiency virus; IQR, interquartile range.